Browse IL17A

Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF06083 Interleukin-17
Function

Ligand for IL17RA and IL17RC (PubMed:17911633). The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC (PubMed:18684971). Involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines (PubMed:8676080).

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002521 leukocyte differentiation
GO:0002532 production of molecular mediator involved in inflammatory response
GO:0002534 cytokine production involved in inflammatory response
GO:0002573 myeloid leukocyte differentiation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0009306 protein secretion
GO:0009620 response to fungus
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032627 interleukin-23 production
GO:0032635 interleukin-6 production
GO:0032667 regulation of interleukin-23 production
GO:0032675 regulation of interleukin-6 production
GO:0032747 positive regulation of interleukin-23 production
GO:0032755 positive regulation of interleukin-6 production
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045672 positive regulation of osteoclast differentiation
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050832 defense response to fungus
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0070555 response to interleukin-1
GO:0071347 cellular response to interleukin-1
GO:0072537 fibroblast activation
GO:0072604 interleukin-6 secretion
GO:0098542 defense response to other organism
GO:1900015 regulation of cytokine production involved in inflammatory response
GO:1900017 positive regulation of cytokine production involved in inflammatory response
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903532 positive regulation of secretion by cell
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1904951 positive regulation of establishment of protein localization
GO:2000778 positive regulation of interleukin-6 secretion
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-448424: Interleukin-17 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL17A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL17A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26785144Kidney CarcinomaPromote immunityThese findings suggest that synthetic agonists of RORγt should activate TC17/TH17 cells (with concomitant reduction in the Tregs population), repress PD-1, and produce IL17 in situ (a factor associated with good prognosis in cancer).
26719303Colorectal CarcinomaPromote immunity (infiltration)Indeed, owing to IL-17 secretion, CRC-derived Th17 triggered the release of protumorigenic factors by tumour and tumour-associated stroma. However, on the other hand, they favoured recruitment of beneficial neutrophils through IL-8 secretion and, most importantly, they drove highly cytotoxic CCR5+CCR6+CD8+ T cells into tumour tissue, through CCL5 and CCL20 release.
27620275Gastric CarcinomaPromote immunity (infiltration)Proinflammatory IL17 is a critical mediator of the recruitment of neutrophils into the invasive margin by CXC chemokines.
24525743Hepatocellular carcinomaInhibit immunity (T cell function); immunotherapy targetIL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. The tumor-promoting effect of IL-17A was mediated through suppression of antitumor responses, especially CD8(+) T-cell responses. Mechanistic investigations showed that IL-17A induced CXCL5 production by tumor cells to enhance the infiltration of myeloid-derived suppressor cells (MDSC) to tumor sites in a CXCL5/CXCR2-dependent manner. Conversely, IL-17A could also enhance production of IL-1β and IL-23 in MDSC as a positive feedback. These findings offer new insights into how IL-17A influences tumor immunity, with potential implications for the development of tumor immunotherapy.
23022528Lung carcinomaPromote immunityAs modulation of T cell cytokines such as IL-17A has been recently shown to suppress tumor growth in experimental models, anti-cytokine agents emerge as a promising new approach for treatment of lung cancer.
23420584Malignant Splenic NeoplasmInhibit immunity (T cell function)Here, we show that lactic acid, or more specifically the acidification it causes, increases arginase I (ARG1) expression in macrophages to inhibit T-cell proliferation and activation. We show that dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinases, targets macrophages to suppress activation of the IL-23/IL-17 pathway and the expression of ARG1 by lactic acid. DCA treatment decreased ARG1 expression in tumor-infiltrating immune cells and increased the number of IFN-γ-producing CD8+ T cells and NK cells in tumor-bearing mouse spleen.
19471017Melanoma; FibrosarcomaPromote immunityWe skewed CD8(+) T cells to secrete IL-17 through priming in Th17-polarizing conditions. This improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells.
19470694Ovarian CarcinomaPromote immunity (infiltration)Furthermore, through synergistic action between IL-17 and interferon-gamma, Th17 cells stimulate CXCL9 and CXCL10 production to recruit effector T cells to the tumor microenvironment. The levels of CXCL9 and CXCL10 are associated with tumor-infiltrating effector T cells. The levels of tumor-infiltrating Th17 cells and the levels of ascites IL-17 are reduced in more advanced diseases and positively predict patient outcome.
29604293Pancreatic ductal adenocarcinoma; melanoma; colon carcinomaPromote immunityImmune cells that produce interleukin 17A (IL17A) in the chronically inflamed pancreas (chronic pancreatitis) contribute to pancreatic interepithelial neoplasia (PanIN) initiation and progression.
21455984Other Mammary Carcinoma of MouseInhibit immunityTLR4 deficient mice developed more tumors relative to the WT mice. T cells of TLR4 deficient mice produced elevated levels of IL-17 and lower levels of IFN-γ relative to WT mice. IL-12 secreted by CD11c(+) cells was higher in WT mice, whereas greater amounts of IL-23 were produced by CD11c(+) cells from TLR4 deficient mice.
21300825Metastatic Malignant Neoplasm in the LungPromote immunity (T cell function)Reduced tumor progression along with improved T cell function was found in IL-17 KO mice, compared with WT mice.
22186896Lung AdenocarcinomaPromote immunityHere we show, in the lungs of patients with lung adenocarcinoma, an increase in interleukin-17A that is inversely correlated with the expression of T-bet and correlated with the T regulatory cell transcription factor Foxp3. Local targeting of interleukin-17A in experimental lung adenocarcinoma results in a reduction in tumour load, local expansion of interferon-γ-producing CD4(+) T cells and a reduction in lung CD4(+)CD25(+)Foxp3(+) regulatory T cells.
21674477Hepatocellular CarcinomaInhibit immunity (T cell function)Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Accordingly, IL-17 could activate monocytes to express B7-H1 in a dose-dependent manner.Moreover, these IL-17-exposed monocytes effectively suppressed cytotoxic T-cell immunity in vitro; the effect could be reversed by blocking B7-H1 on those monocytes.
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL17A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL17A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1450.449
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0070.99
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2590.569
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8040.467
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9240.567
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6460.72
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1680.473
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL17A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL17A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL17A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL17A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL17A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL17A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL17A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL17A
Nameinterleukin 17A
Aliases IL-17A; IL-17; cytotoxic T-lymphocyte-associated protein 8; CTLA8; IL17; interleukin 17 (cytotoxic T-lymphoc ......
Chromosomal Location6p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL17A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IL17A.
ID Name Drug Type Targets #Targets
DB09029SecukinumabBiotechIL17A1
DB11569IxekizumabBiotechIL17A1